Treatment for Hypermetria

Phase-Based Estimates
1
Effectiveness
2
Safety
The Children's Hospital of Philadelphia, Philadelphia, PA
Hypermetria+2 More
Eligibility
18 - 65
All Sexes
Eligible conditions
Hypermetria

Study Summary

This study is evaluating whether a chemical may help improve heart function in individuals with Friedreich's Ataxia.

See full description

Eligible Conditions

  • Hypermetria
  • Cerebellar Ataxia
  • Friedreich Ataxia
  • Ataxia

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome and 4 secondary outcomes in patients with Hypermetria. Measurement will happen over the course of Change from baseline to 14 days..

14 Days
Incidence of treatment-emergent adverse events as assessed by Common Terminology Criteria for Adverse Events version 5.0.
Day 14
Cardiac 31-Phosphorus-MRS: PCr/ATP Ratio
Concentration of NAD+ in Whole Blood
Grip Strength
Post-Exercise CrCEST

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Trial Design

1 Treatment Groups

Control

This trial requires 10 total participants across 1 different treatment groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 14 days
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 14 days for reporting.

Who is running the study

Principal Investigator
S. M.
Shana McCormack, Attending Physician
Children's Hospital of Philadelphia

Closest Location

The Children's Hospital of Philadelphia - Philadelphia, PA

Eligibility Criteria

This trial is for patients born any sex between 18 and 65 years old. There are 2 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Molecular diagnosis of Friedreich's Ataxia (FA).
Males and females, ages 18 years to < 65 years.

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is hypermetria?

Add answer

Hypermetria is a rare (1%) neurological disorder characterized by oversensitivity of the visual processing system causing an exaggeration of visual spatial perception. These patients fail to discriminate between two near objects that are approximately the same size and of two similar or dissimilar objects located at approximately the same distance from each other. Patients have difficulty in performing tasks requiring the simultaneous processing of the visual and the manual (both right and left hands) systems, and they have deficits in discriminating right and left hands. The patients were able to accurately fixate on objects with their eyes but had difficulty using both hands to manipulate items.

Unverified Answer

What are the signs of hypermetria?

Add answer

This sign is a non-specific sign of the frontal lobes, and is particularly associated with the loss of the ability to attend to the immediate environment. It usually manifests as a difficulty in selecting objects, or in discriminating between a simple and a complex stimulus. It may be difficult to identify on clinical presentation.

Unverified Answer

Can hypermetria be cured?

Add answer

In children with chronic, persistent hypermetria (> or =5 mm of vertical/horizontal deviation), most exhibit a normal neuropsychological profile but show a statistically significant increase in the number of perceptual anomalies (more or faster auditory discrimination, better visual and object identification), or of dysmetria (greater than 5 mm) after completing the treatment. However, these children did not report noticeable improvements in the number of visual field defects.

Unverified Answer

How many people get hypermetria a year in the United States?

Add answer

around 2 million people in the United States are diagnosed with dysdiadochokinesia, which is a common feature of progressive supranuclear palsy. The proportion of patients who have a symptom duration of > 3 yr is relatively constant over the 12 yr period (around 1:4). Future longitudinal studies of dysdiadochokinesia are warranted.

Unverified Answer

What causes hypermetria?

Add answer

Hypermetria is a result of dysfunction of the normal mirror neuron system. Although the main underlying physiological processes, neuronal activity in the primary somatosensory cortex, are not all fully understood, it is thought possible that in hypermetrica(s), an abnormal signal processing in the brain leads to a mismatch in somatosensory information with a normal body schema, in effect resulting in a distorted representation of body position in the primary somatosensory cortex.

Unverified Answer

What are common treatments for hypermetria?

Add answer

A few common treatments for hypermetria can include gabapentinoids or ketamine as well as surgical and/or psychotherapy. The use of gabapentinoids is limited to a particular subset of people with hypermetria.

Unverified Answer

What is the primary cause of hypermetria?

Add answer

Hypermetria of vision often has a primary neurologic, traumatic, or ocular/refractive cause. When hypermetria has a specific cause of neurologic, traumatic, or ocular/refractive, it indicates a primary disorder of vision, or primary problem with the brain itself. [Power (https://www.withpower.com/d/hypermetria_problems#) gives answers to common questions about hypermetria.

Unverified Answer

Have there been any new discoveries for treating hypermetria?

Add answer

Hypermetria was first noted during the early Middle Ages, and some interesting treatment options have come through during that time. There are currently a great number of treatments available for hypermetria; the most promising therapies are those with the smallest side effects, including medications that target the central nervous system as well as the peripheral nervous system. Clinical trials such as the AIM-CVS, AIM-CVS2, and the PIP-CVS are conducting in different areas of the United States focusing on different aspects of hypermetria.

Unverified Answer

How does treatment work?

Add answer

Although some of the symptoms of hypermetria can have their genesis in a disease process other than hypermetria, the pattern of behavior exhibited by hypermetria patients during experimentation and in-the-practice environments strongly suggests that hypermetria-related symptoms are not merely secondary to hypermetria itself. Rather, hypermetria involves a processing cascade in which, while the 'information that has been created from and around, within and around other sensory modalities is the key to understanding, creating, and remembering, the sensory input produced by the individual sensory senses themselves’ [Keller et al.

Unverified Answer

Has treatment proven to be more effective than a placebo?

Add answer

Although several medications have been used in treatment of patients who had hypermetria, no evidence suggests that any medication has been more effective than a placebo in altering hypermetria.

Unverified Answer

Who should consider clinical trials for hypermetria?

Add answer

There are a wide range of opinions about the clinical trial options for hypermetria. The current treatment options are largely limited to pharmaceutical drug therapy, and in certain cases surgery. A more balanced approach to clinical trials of hypermetria could better meet the needs of those patients most likely to want to try them. In particular, those patients who are willing or capable of doing self-instruction are the most likely to want to try clinical trials. In the United States, we have an immense demand for clinical trials of new treatment options for multiple sclerosis. Using information about the clinical trials, medical professionals may be able to better meet the clinical trial needs and also help patients to reach their maximal potential regarding functional recovery.

Unverified Answer

Is treatment typically used in combination with any other treatments?

Add answer

Recent findings suggest that most patients received multiple treatments which do not significantly change the time to relapse, or death. However, most patients received a treatment that was not typically used in combination with another treatment.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Hypermetria by sharing your contact details with the study coordinator.